NCT07468903Recruiting
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
Phase II Trial of Focal Radiation Therapy in Patients With Prostate Cancer
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer. Prostate cancer is the most diagnosed cancer in men and there are many treatments available, including surgery and radiation therapy. Although surgery and radiation therapy improve survival urinary and sexual function can be significantly affected and can be long lasting. HDR-BT, a type of focal radiation therapy also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving HDR-BT may be effective in providing local control while reducing side effects in patients with prostate cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 9 Mar 2026
- Start date
- 11 May 2026
- Primary completion date
- 11 May 2031
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT07468903
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 11 May 2026 to the primary completion date, 11 May 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiotherapy to the pelvis
Other illness
- Radiographic nodal or distant metastatic disease
- Gleason score \> 6 disease outside intended gross target volume (GTV)/target region(s)
Other
- Lesion(s) comprising \> 40% of total prostate volume
Who the study is looking for
- Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy
- Multiparametric MRI (mp-MRI) confirmed lesion(s)
- No distant or locally advanced disease on standard staging exams as indicated
- Bone scan and abdominopelvic computed tomography (CT)/MRI OR
- PSMA PET
- Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0/1 within 60 days prior to enrollment
- Age ≥ 40
Age in the registry: 40 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.